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As new inﬂuenza virus strains emerge, ﬁnding new mechanisms to control infection is imperative. In this
study, we found that we could control inﬂuenza infection of mammalian cells by altering the level of
glucose given to cells. Higher glucose concentrations induced a dose-speciﬁc increase in inﬂuenza
infection. Linking inﬂuenza virus infection with glycolysis, we found that viral replication was
signiﬁcantly reduced after cells were treated with glycolytic inhibitors. Addition of extracellular ATP
after glycolytic inhibition restored inﬂuenza infection. We also determined that higher levels of glucose
promoted the assembly of the vacuolar-type ATPase within cells, and increased vacuolar-type ATPase
proton-transport activity. The increase of viral infection via high glucose levels could be reversed by
inhibition of the proton pump, linking glucose metabolism, vacuolar-type ATPase activity, and inﬂuenza
viral infection. Taken together, we propose that altering glucose metabolism may be a potential new
approach to inhibit inﬂuenza viral infection.
& 2013 Elsevier Inc. All rights reserved.Introduction
Inﬂuenza viruses are respiratory viruses, and members of the
orthomyxovirus family of virus. Inﬂuenza viral infection of cells is
mediated by the viral proteins hemagglutinin (HA) and matrix
protein 2 (M2) (Palese and Shaw, 2007). HA binds to sialic acid
residues on cell surfaces, triggering endocytosis of the virus into
an endocytic vesicle. This acidic pH within the endosome pro-
motes two actions: (1) HA changes conformation and fuses the
viral envelope with the endosome membrane, and (2) the M2
proton channel becomes activated and transports protons into the
viral core (Palese and Shaw, 2007). M2 activity lowers the pH
within the virion allowing for viral uncoating (Betakova, 2007),
and subsequent transport of the viral genome from the virion into
the cytosol (Palese and Shaw, 2007).
The cellular vacuolar-type H+ ATPase (V-ATPase), located
within endosomal membranes, other intracellular compartments,
as well as the plasma membrane, has been identiﬁed to be
involved in inﬂuenza viral entry by maintaining the acidic pH
necessary within endosomes for viral release (Adamson et al.,
2011; Guinea and Carrasco, 1995; Jefferies et al., 2008). V-ATPase
protein complexes are multi-molecular proton pumps composed
of a peripheral V1 domain consisting of subunits A, B, C, D, E, F, G,ll rights reserved.
ng, Department of Biology,
ro, NC 27402, USA.
n).and an integral V0 subcomplex containing subunits a, c, d and e,
with subunit c consisting of different isoforms, c′ and c″ (Jefferies
et al., 2008). The V-ATPase pumps couple ATP hydrolysis to the
transport of protons from the cytoplasm into the lumens of
endosomes or organelles. Speciﬁcally, ATP binds to catalytic sites
on the V1 domain, (on the A and B subunits). This activity drives
proton translocation from the cytoplasm into the lumen, acidifying
the interior of intracellular compartments necessary for multiple
cellular processes (Jefferies et al., 2008). Previous work has
demonstrated that inhibition of the V-ATPase (by the drug
baﬁlomycin A1) inhibits inﬂuenza viral infection (Adamson et al.,
2011; Guinea and Carrasco, 1995; Ochiai et al., 1995; Perez and
Carrasco, 1994). Likewise, overexpression of speciﬁc subunits of
the pump (V1A, V1B, V1C) enhanced viral infection (Adamson et al.,
2011). Therefore, the V-ATPase provides an interesting target in
relation to limiting inﬂuenza viral infection.
V-ATPase activity is regulated through disassembly of the V1
and V0 domains. This process helps regulate the pH levels of
endosomes and organelles inside the cell (Kane, 2006). One of the
mechanisms that causes the dissociation of V-ATPase is glucose
depletion (Beyenbach and Wieczorek, 2006; Kane, 2006). This
dissociation mechanism was ﬁrst observed in yeast. In addition,
V-ATPase assembly on membranes can be stimulated by glucose;
this has been shown to be mediated by the phosphatidylinositol
3-kinase signaling pathway in renal epithelial cells (Sautin et al.,
2005). Stimulation by glucose has also been shown to increase
V-ATPase activity in MDCK and A549 cells (Marjuki et al., 2011).
Furthermore, studies with yeast and mammalian cells have
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V-ATPases and glycolytic enzymes (Lu et al., 2001, 2004; Su et al.,
2003). Lu et al. found an interaction between the V-ATPase a, B,
and E subunits and the aldolase enzyme, the glycolytic enzyme
that converts fructose-1, 6-biphosphate into glyceraldehyde-
3-phosphate (step 4 of glycolysis) (Lu et al., 2001, 2004). Further-
more, Lu et al. have shown that there is an increase in the
interaction between aldolase and the subunits of V-ATPases when
glucose levels are increased (Lu et al., 2004). Su et al. have shown
in human kidney cells that the rate limiting enzyme of the
glycolytic pathway, phosphofructokinase 1 (PFK-1), which med-
iates step 3 of glycolysis, interacts with the V-ATPase a subunit
(Su et al., 2003). A study conducted in our lab identiﬁed
glyceraldehyde-3-phosphate dehydrogenase (GAPDH; catalyzes
step 6 of glycolysis) as a genetic modiﬁer of M2 ion channel
activity in a Drosophila model system (unpublished data).
Since the V-ATPase is ATP-dependent, sufﬁcient ATP levels are
needed to maintain the pump's assembly and activity. In fact,
pump disassembly has been attributed to a reduction in ATP levels
(Parra and Kane, 1998). Taken together, reductions in glucose
levels or the inhibition of glycolysis would likely promote V-
ATPase disassembly, reduce acidiﬁcation of endosomes, thus
inhibiting inﬂuenza M2 and activities, and ultimately inhibit
inﬂuenza viral replication.
Antiviral drugs for the treatment of inﬂuenza infection mainly
target viral proteins such as neuraminidase (NA) and M2, however
these drugs typically lose their effectiveness as the virus mutates
(Betakova, 2007; Ison, 2011; Nguyen et al., 2012). Therefore, it is
essential to identify more alternatives to control inﬂuenza infec-
tion, including targeting the host cellular processes that the virus
utilizes to promote infection and replication. In this work, we
explored how inﬂuenza virus infection is affected by the manip-
ulation of glucose levels and glycolysis. We found that viral
infection is dependent upon abundant glucose supplies, and that
inhibition of glycolysis limits viral infection; these events occur in
accordance with V-ATPase disassembly.Results
Higher glucose concentrations correlate with higher levels of
inﬂuenza A H1N1 viral infection
We previously identiﬁed several genetic modiﬁers of inﬂuenza
M2 activity in our Drosophilamodel system (Adamson et al., 2011).
In our genetic screen we also identiﬁed that a mutation in the
Drosophila gene Gapdh1 suppressed M2 activity (data not shown).
The human homolog of Gapdh1 is the glycolytic enzyme glycer-
aldehyde 3-phosphate dehydrogenase, which mediates step six of
glycolysis. This suggested to us a link between glucose metabolism
and inﬂuenza viral infection. To determine if inﬂuenza viral
infection was dependent upon glucose metabolism, we initially
examined the efﬁciency of inﬂuenza viral infection of MDCK cells
grown at varying glucose concentrations, which were subse-
quently infected with inﬂuenza A H1N1. We observed that higher
glucose levels led to an increase in viral protein accumulation
within infected cells, as judged by HA protein levels, as well as an
increase in the percentage of infected cells (Fig. 1). We found a
signiﬁcant increase in the percentage of infected cells in the higher
glucose level conditions (4–6 mg/ml), compared to the control
treatment (1 mg/ml) (P≤0.05) (Fig. 1E). To ensure that the changes
in infection were not due to viability changes across the different
glucose concentrations, we performed viability tests on MDCK
cells treated with a glucose concentration series, and found no
signiﬁcant changes in cell viability at the different glucose con-
centrations (Fig. 2).Inhibition of hexokinase with 2-DG and 3-BrPa lowered inﬂuenza
viral infection/replication
To determine if the metabolism of glucose via glycolysis was
necessary for viral infection, we tested the effect of glycolytic
inhibitors upon inﬂuenza infection. 2-deoxyglucose (2-DG) is an
analog of glucose and a competitive inhibitor of hexokinase, the
ﬁrst enzyme of glycolysis (Pelicano et al., 2006). 3-bromopyruvate
(3-BrPa) is an alkylating agent that inhibits hexokinase (Pelicano
et al., 2006). Lonidamine (LND) is a molecule that dissociates
hexokinase from mitochondria and inhibits hexokinase (Pelicano
et al., 2006). MDCK cells were grown for 24 h at high glucose levels
containing 2-DG (0, 0.25, 2, or 5 mM), 3-BrPa (0, 30, 300, or 600 mM)
or LND (0, 6, 62.5, or 200 mM). Cells were subsequently infected with
inﬂuenza A H1N1 for 24 h. Cells were immunostained with an anti-
HA antibody to detect infected cells. Viral infectionwas reduced by at
least 90% with 2-DG treatment (Fig. 3A), and by at least 80% with
3-BrPa treatment (Fig. 3B) when compared to the control treatments.
Unexpectedly, we found that cells treated with LND became
signiﬁcantly more infected as we increased the levels of this inhibitor
(Fig. 3C). We subsequently found that LND is reported to be an
inhibitor of hexokinase in the cancer cells only, and that LND actually
increases glycolysis in the normal cells (such as the ones we used
here) (Floridi et al., 1981). To determine how LND would affect
inﬂuenza viral infection of the cancer cell line, we grew the lung
carcinoma cell line A549 at high glucose containing 0, 6, 62.5, or
200 μM LND for 24 h. Cells were infected with inﬂuenza A H1N1 for
24 h, then immunostained with anti-HA antibody. The number of
infected cells was signiﬁcantly reduced by LND treatment in a dose-
dependent manner, however the viability of the cells was also
reduced, especially at the highest dose of LND (data not shown).
Therefore we found that LND is not an effective inhibitor in relation
to viral infection, as it increased infection in normal cells, but was
toxic to cancer cells.
Addition of extracellular ATP restored inﬂuenza viral infection
We found that 2-DG and 3-BrPa were effective inhibitors of
inﬂuenza viral infection; viral infection was completely inhibited
with higher levels of 2-DG. As the main purpose of glycolysis and
further metabolism is to generate ATP, we investigated whether
the addition of extracellular ATP could restore inﬂuenza viral
infection. Cells grown in high glucose were treated with the
inhibitor 2-DG (at 5 mM to ensure complete inhibition) for 24 h,
then cells were simultaneously infected with inﬂuenza virus and
treated with 0, 10, 25, 50 or 100 μM ATP. Immunostaining was
performed 24 h later with an anti-HA antibody to detect infected
cells. Fig. 4 shows that viral infection was restored when ATP was
added, in a dose-dependent manner, seeming to have a maximal
effect upon infection at 50 μM.
High glucose levels increased V-ATPase proton pump assembly in
mammalian cells
Previous work has demonstrated that V-ATPase pump activity
is down-regulated by glucose depletion, through disassembly of
the peripheral V1 and the integral V0 domains in yeast cells, and
stimulated by increased glucose levels (Beyenbach and Wieczorek,
2006; Kane, 2006; Marjuki et al., 2011). Assembly of the pump
components onto intracellular compartment membranes was
associated with a more punctate localization pattern (Parra and
Kane, 1998). To examine pump localization in mammalian cells
differing glucose concentrations, we immunostained A549 and
HeLa cells that had been grown in either low or high glucose levels
(Fig. 5). Human cells were utilized for this analysis because our
anti-V-ATPase pump protein antibodies do not recognize canine
Fig. 1. Increased levels of glucose increased inﬂuenza viral infection of MDCK cells. (A–D) MDCK cells were grown in 1–6 mg/ml glucose as indicated then infected with
inﬂuenza A H1N1 for 24 h. Cells were subsequently ﬁxed and stained with anti-HA-antibody (red). Cells were also stained with Hoescht stain (blue) to identify nuclei.
Confocal imaging was performed. (E) Graph representing the percentage of infected cells at the differing glucose levels. n indicates a P-value≤0.05 compared to 1 mg/ml.
At least four separate ﬁelds of cells were counted for each condition as speciﬁed in Materials and Methods.
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pump assembly at low glucose (Fig. 5A and C), and an increase in
pump assembly at high glucose levels, as determined by the
punctate localization pattern seen in Fig. 5B and D. This staining
pattern was conﬁrmed by staining for the V1B subunit (data not
shown).
To correlate V-ATPase pump localization with increased proton
transport activity, we grew MDCK cells in low or high glucose and
examined the relative pH of intracellular compartments with the
pH-sensitive dye SNARF-1. This dye emits different wavelengths
according to pH (Han and Burgess, 2010). We found that, relative
to the low glucose condition, the cells grown in high glucose had a
greater number of acidic compartments, as well as a lower pH inthese compartments (Fig. 6 and Table 1). Taking the ratios of
acidic/basic staining intensities, we found that the cells grown in
high glucose had an average 3.7 fold increase of the acidic/basic
ratio, suggesting that cells grown in high glucose have more acidic
compartments than those grown in low glucose (Table 1), corre-
lating increased assembly in high glucose with increased proton
transport activity.
V-ATPase protein synthesis was not induced by high glucose
concentrations
To determine if the more punctuate localization pattern or
increased activity of the V-ATPase was a result of increased pump
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Western blot. A549 cells were grown in 1, 2, 4, and 6 mg/ml
glucose, and the V-ATPase V1A1 and V1B1/2 protein levels were
determined (Fig S1 shows V1A1 protein levels within A549 cells).
Protein levels of the V-ATPase pump subunits V1A or V1B (data not
shown) did not increase with increased glucose levels, indicating
that the increase we saw in assembly was not due to an increase in
pump subunit protein production, but to localization of the pump
subunits on intracellular compartment membranes.
V-ATPase disassembly could be reversed by the addition of ATP
As the localization of the V-ATPase on intracellular membranes
was found to be dependent upon glucose levels, we investigated
whether the need for glucose could be bypassed by the addition of
extracellular ATP. A549 cells were grown in low or high glucose for
24 h, and were subsequently treated with 50 μM ATP for 10 min or
one hour prior to ﬁxation and staining for the V1A subunit. Fig. 7
shows that in low glucose, assembly of the pump could be
stimulated by ATP treatment within 10 min, with the assemblyFig. 2. Differing glucose levels do not affect viability of cells at the time of infection.
MDCK cells were grown in 1–6 mg/ml glucose as indicated for 24 h. Cell viability
was determined by incubating cells in Guava ViaCount reagent and assayed by ﬂow
cytometry. The percentage of viable cells is presented. The graph represents three
separate trials; the slight variation in cell viability was not statistically signiﬁcant.
Fig. 3. Inﬂuenza viral infection is inhibited by glycolytic inhibitors. MDCK cells were tre
(0, 30, 300 and 600 mM) (B), or LND (0, 6, 62.5 and 200 mM,) (C) and subsequently inf
percentage of infected cells was determined. n number of infected cells for each concen
separate ﬁelds of cells were counted for each condition as speciﬁed in Materials and Mmatching that of high glucose by 1 h of ATP treatment (compare
Fig. 7A, C, and E). Addition of ATP to cells grown at high glucose
did not appear to have any further effect upon assembly (compare
Fig. 7B, D, and F).
To examine whether V-ATPase localization was linked to
glycolysis, we treated A549 cells, grown in high glucose, with
the glycolytic inhibitor 2-DG. V-ATPase assembly was reduced
after 2-DG treatment (Fig. 8B). This disassembly could be reversed,
however, after treatment with 50 μM ATP for 1 h (Fig. 8C).The increased viral infection associated with high glucose levels is
reversed by inhibition of V-ATPase
To conﬁrm that the increased frequency of inﬂuenza virus
infection that we noted at higher glucose levels was indeed
due to the increased activity of the V-ATPase, we grew MDCK
cells in low and high glucose levels, then subsequently treated
the cells with baﬁlomycin, a V-ATPase inhibitor (Drose andated for 24 h with the glycolytic inhibitors 2-DG (0, 0.25, 2, and 5 mM) (A), 3-BrPa
ected with inﬂuenza A H1N1 for 24 h. Cells were immunostained for HA and the
tration when compared to the control treatment had a P-value≤0.05. At least four
ethods.
Fig. 4. The addition of ATP reverses the glycolytic inhibitor-mediated inhibition of
inﬂuenza viral infection. MDCK cells were treated with 5 mM 2-DG for 24 h, then
infected with inﬂuenza virus in the presence of extracellular ATP (0–100 mM as
indicated). Cells were immunostained for HA and the percentage of infected cells
was determined. n P-value≤0.05, comparing each ATP treatment group to the
control () ATP group. At least four separate ﬁelds of cells were counted for each
condition as speciﬁed in Materials and Methods.
Fig. 5. The V-ATPase pump localizes to intracellular compartments to a greater degree at high glucose levels. A549 (A-B) or HeLa cells (C-D) were grown in low or high
glucose for 24 h and immunostained with anti-V1A1 antibody. Confocal imaging was performed, each with identical acquisition settings. Insets are zoomed-in images.
Arrows refer to the V-ATPase localization; note the more punctate pattern of localization at the higher glucose concentrations (B, D).
Fig. 6. High glucose leads to more acidic intracellular compartments. MDCK cells were grown in low or high glucose for 24 h then incubated in SNARF-1 dye. Live cells were
imaged by exciting the dye with a 488 nm wavelength, then capturing images at 580 nm and 640 nm wavelengths. The images from the 580 nm emission (which denotes
acidity) are presented.
Table 1
Intracellular compartments in high glucose-treated cells are more acidic.
Glucose level n Ratio of 580 nm/635 nm intensities
Low 57 0.2770.14
High 67 1.070.34 (P¼5.9410–22)
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virus. Cells were immunostained for the inﬂuenza HA protein to
identify infected cells. Fig. 9 shows that baﬁlomycin A1 treatment
negated the effect of increased glucose upon infection success,
further correlating that the increased infection was mediated by
the increased activity of the V-ATPase pump.Discussion
Inﬂuenza infection is a constant and major public health
concern. Many current antiviral drugs that target the inﬂuenza
viral envelope proteins are rendered ineffective over time, as
different viral strains emerge. Thus, it is important to identify
alternative ways to control inﬂuenza viral infection, by not only
targeting viral particle proteins, but by also targeting the host
cellular processes that the virus may utilize for infection and
replication.
Inﬂuenza virus is dependent upon many host cellular mole-
cules in order to infect, replicate inside, and egress from a cell
[reviewed in (Watanabe et al., 2010)]. An early event important for
the viral life cycle is the uncoating of viral particles, and the
subsequent release of viral ribonucleoprotein (vRNP) complexes
Fig. 7. ATP reverses the disassembly of the V-ATPase due to low glucose. A549 cells were grown in the presence of low glucose (A, C, and E) or high glucose (B, D, and F) for
24 h. Cells were treated with no ATP (A-B), or 50 μM ATP for 10 min (C-D) or 1 h (E-F), then immunostained with anti-V1A1 antibody. Confocal imaging was performed, each
with identical acquisition settings.
Fig. 8. V-ATPase assembly can be reversed by glycolytic inhibition. A549 cells were grown in high glucose and subsequently treated with 2 mM 2-DG for 24 h (B). A subset of
cells were treated with ATP for the last hour prior to ﬁxation and staining with an anti-V1A antibody (C). Confocal imaging was performed, each with identical acquisition
settings.
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within endosomes, which in itself occurs in a multi-step process.
Initially the virus-containing endosome is transported to the
periphery of the nucleus, the pH is lowered to pH 6, then a
second acidiﬁcation event decreases the pH to pH 5
(Lakadamyali et al., 2003). This acidic pH is created by the actionof the cellular V-ATPase; inhibition of the V-ATPase suppresses
viral infection. Speciﬁc subunits of the V-ATPase have been
identiﬁed as particularly important for inﬂuenza viral infection,
including the V1 subunits A, B, and C, as well as the V0 subunits B,
C, and D1 (Adamson et al., 2011; Hao et al., 2008; Watanabe et al.,
2010). The action of the V0D1 subunit appears to have some
Fig. 9. Inhibition of the V-ATPase reverses the high glucose-mediated increase of infection. MDCK cells were grown in low or high glucose for 24 h, then infected with
inﬂuenza A H1N1. At the time of infection, cells were also treated with 5 nM baﬁlomycin A1 (C). Cells were immunostained 48 h post-infection for HA (red) and stained with
Hoescht (blue). (D) The percent of infected cells at each condition is presented. n denotes that the difference between high and low glucose has a Po0.05; nn denotes that the
high glucose plus baﬁlomycin A1 data is different from low or high glucose alone, both with a Po0.05. At least four separate ﬁelds of cells were counted for each condition as
speciﬁed in Materials and Methods.
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virus speciﬁcally manipulates this subunit to perhaps trigger
endosome acidiﬁcation at the nuclear periphery (Hao et al., 2008).
In this study, we targeted the V-ATPase proton pumps, which
regulate the pH of intracellular compartments, in order to control
inﬂuenza infection. In this report we demonstrated that regulating
the V-ATPase pump activity through glucose metabolism may be a
useful approach in controlling and inhibiting inﬂuenza replication
during infection of mammalian cells. As previously mentioned, the
V-ATPase activity can be regulated through glucose depletion
leading to disassembly of the V1 and V0 domains (Beyenbach
and Wieczorek, 2006; Kane, 2006). Additionally, in yeast cells it
has been shown that V-ATPase assembly is modulated by the
relative concentration of extracellular glucose (Parra and Kane,
1998). Under high glucose conditions in mammalian cells we have
provided additional evidence for a higher activity of the V-ATPase
(Figs. 5 and 6), which is consistent with the fact that the pumps
couple ATP hydrolysis and activity. Furthermore, we have linked
glucose levels with V-ATPase activity in relation to inﬂuenza viral
infection (Fig. 1). Our results are different than those of Marjuki
et al., which found that glucose stimulation promoted V-ATPase
activity but did not alter inﬂuenza viral infection of MDCK or A549
cells (Marjuki et al., 2011). The reason for the discrepancy is not
clear; however our treatment conditions (media formulations,
glucose concentrations, MOI, and timing) were different, and
may have allowed more sensitivity in our assays.
As we found that V-ATPase assembly/activity was based upon
available glucose levels, we studied the inhibition of glycolysis
upon viral infection levels. Glycolysis is the process by which
glucose metabolism occurs to generate a net gain of two ATP, two
NADH+ and two molecules of pyruvate. The pyruvate molecules
are further metabolized to produce more ATP. Speciﬁc enzymes
catalyze each stage of glycolysis. Previously, researchers have
demonstrated direct links between glycolytic enzymes and speciﬁcV-ATPase subunits (Lu et al., 2001, 2004, 2007; Parra and Kane,
1998; Su et al., 2003). We analyzed the effects of inhibition of the
hexokinase enzyme, the ﬁrst enzyme of the glycolytic pathway.
With a reduction of glycolysis, the intracellular ATP level would
consequently be lowered, leading to a decrease in pump assembly/
activity (as we demonstrated in Fig. 8). We showed that inhibition
of the glycolytic pathway with the hexokinase inhibitors 2-DG and
3-BrPa reduced inﬂuenza infection. A 92.8% decrease in infection
was observed with the 5 mM 2-DG treatment, and a reduction of
81.8% with the 600 mM 3-BrPa treatment, when compared to the
control cells. Infection was not completely inhibited at our highest
dose of 3-BrPa (600 mM); higher 3-BrPa concentrations may be
required for complete inhibition of inﬂuenza infection. While
infection was inhibited with 2-DG and 3-BrPa, “inhibition” of
hexokinase with LND signiﬁcantly increased inﬂuenza infection
in MDCK cells. These results likely were observed because LND
reportedly enhances glycolysis in normal cells, only causing a
decrease in glycolysis in cancer cells (Floridi et al., 1981). This
selection in activity may be due to LND acting upon the
mitochondrially-bound hexokinase, which is usually absent in
normal cells (Floridi et al., 1981). This result actually supports
our hypothesis that infection is tied to glycolysis, since LND would
cause increased glycolysis, and did cause increased infection in
MDCK cells.
ATP is considered to activate V-ATPase by binding to the
catalytic sites on the A and B subunits of the pump. In the present
study, we bypassed glucose metabolism through the addition of
extracellular ATP. Addition of extracellular ATP after glycolytic
inhibition with 2-DG restored inﬂuenza infection in mammalian
culture cells, presumably through reassembly of the V1 and V0
domains (as shown in Figs. 4 and 8). This suggests that in relation
to the inﬂuenza viral infection process, glycolysis is not absolutely
required to take place in order for the V-ATPase to function in
endosomes, as long as additional ATP is provided.
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regard to patients and animal models with diabetes. A study that
characterized the link between human patients with an active
H1N1 infection and diabetes found that patients with diabetes had
more severe viral infections and inﬂuenza symptoms (Allard et al.,
2010). In a mouse model system, it was found that inﬂuenza A
virus replicated to signiﬁcantly higher levels in the lungs of
diabetic mice than in non-diabetic mice; these higher levels were
proportional to higher glucose levels, and could be reversed with
insulin treatment (however this effect was only seen with H3N2,
not H1N1, virus) (Reading et al., 1998).
Overall, we have found that we can limit inﬂuenza viral
infection by manipulating the energy available (either in form of
glucose or ATP) for the V-ATPase pumps to function. Cells normally
grown in a high glucose medium (4–6 mg/ml glucose), when
switched to a low glucose medium (1 mg/ml) were much less
susceptible to infection by the inﬂuenza virus. Inhibition of glucose
metabolism yielded the same effect. The infection rate under these
varying conditions correlated perfectly with the assembly/disas-
sembly of the V-ATPase pump under the same conditions. There-
fore, the lowering of glucose levels and/or inhibition of glycolysis
may be an avenue for the reduction of infection in mammals.Materials and Methods
Cell culture
HeLa and Madin-Darby Canine Kidney (MDCK) cells (ATCC)
were cultured in Dulbecco's Modiﬁed Eagles Medium (DMEM).
A549 cells (lung carcinoma, ATCC) were cultured in F-12 Ham's
medium. All media was supplemented with 10% Fetal Bovine
Serum (FBS) as well as penicillin/streptomycin and antifungal
agents. Cells were maintained at 37 1C in an air jacketed incubator
with 5% CO2.Inﬂuenza viral infection
Cells were plated (8104 cells) in 35 mm cell culture dishes,
with coverslips. Infection medium was prepared with inﬂuenza A
H1N1 virus (A/PR/8/34) (ATCC) with a Multiplicity of Infection
(MOI) of 1 (or an MOI of 0.25 in the case of LND), in low (1 mg/ml)
glucose DMEM (with no additives), along with 1 μg/ml trypsin,
0.125% BSA, and 1% HEPES. Cells were infected with inﬂuenza A
H1N1 for 24 h, washed with 1 PBS, and new medium was added
accordingly for 24 h.Immunostaining
Cells grown on coverslips were rinsed in 1 PBS and ﬁxed in
4% paraformaldehyde in PBS at room temperature for 15 min. Cells
were incubated in incubation mix (1 PBS, 0.3% BSA, 0.1% Triton X,
5% goat serum) for 10 min. Cells were incubated for 1 h at 37 1C
with primary antibody [anti-HA, anti-V1A, anti- V1B antibodies (all
from Santa Cruz), diluted 1:200 in incubation mix]. Cells were
washed 4 times with 1 PBS followed by incubation for 40 min at
37 1C with secondary antibody [goat-anti-mouse-CY3, donkey-
anti-rabbit-CY3 (Jackson Immuno Research Laboratories)] diluted
1:400 in incubation mix. Cells were washed 4 times, including one
wash containing Hoescht stain (diluted 1:2000 in 1xPBS). Cover-
slips were mounted in Fluorescent Mounting Medium (DakoCyto-
mation). Images were taken with an Olympus confocal
microscope. Staining intensities were quantiﬁed with FluoView
software.Western blotting
Cells were washed in 1 PBS, resuspended in ELB buffer
(0.25 M NaCl, 0.1% NP40, 50 mM HEPES pH 7, 5 mM EDTA,
protease inhibitors) and freeze-thawed twice. Equal amounts of
protein were loaded onto a 10% SDS-PAGE gel, electrophoresed,
and transferred to Immobilon (Millipore). The membrane was
blocked in 1 PBS, 0.1% Tween 20, 5% bovine serum albumin
and incubated in primary antibody [anti-V1A, anti-tubulin (Devel-
opmental Studies Hybridoma Bank)] diluted 1:200 in blocking
solution, for 1 h at room temperature, and then washed with
1PBS, 0.1% Tween 20. The membrane was incubated with goat-
anti-mouse-horseradish peroxidase secondary antibody (Jackson
ImmunoResearch Laboratories), diluted 1:10,000 in blocking solu-
tion, at room temperature for 60 min. The membrane was washed
and bound antibody was viewed using SuperSignal (Thermo
Scientiﬁc Pierce).
Treatments
2-deoxyglucose (2-DG), 3-bromopyruvate (3-BrPa), Lonidamine
(LND), adenosine 5'triphosphate disodium salt hydrate (ATP), and
baﬁlomycin A1 were purchased from Sigma.
Glycolytic inhibitors: MDCK or A549 cells were plated in high
glucose (4.5–6 mg/ml) DMEM. Cells were treated 24 h later with 2-
DG (0, 0.25, 2, and 5 mM), 3-BrPa (0, 30, 300, and 600 mM) or LND
(0, 6, 62.5, and 200 mM,) [concentrations were established from
(Hulleman et al., 2009)], each for 24 h prior to infection with
inﬂuenza A H1N1. 24 h post-infection, cells were washed with
1PBS and new medium was added, including the inhibitors.
Immunostaining was conducted as previously described using an
anti-HA primary antibody and a goat-anti-mouse-CY3 secondary
antibody (Jackson Immuno Research Laboratories).
ATP: To promote infection: MDCK cells were plated in high
(4.5–6 mg/ml) glucose DMEM and treated 24 h later with 2-DG
(5 mM). 24 h later, cells were treated with ATP (0, 10, 25, 50 or
100 mM) [concentrations were established from (Probst et al.,
1989)] along with inﬂuenza A H1N1 and the inhibitor for 24 h.
Cells were washed and medium replaced (with no extra ATP nor
inhibitor). Twenty four hours later, cells were ﬁxed and stained
with an anti-HA antibody as previously described.
ATP: To promote V-ATPase assembly: A549 cells were plated in
low (2 mg/ml) or high (6 mg/ml) glucose medium for 24 h. ATP
(50 μM) was added for 10 min or 1 h, then the cells were ﬁxed and
stained for V1A as previously described.
Baﬁlomycin A1: MDCK cells were plated in low (1 mg/ml) or
high (6 mg/ml) glucose medium, and 24 h later were treated with
0 or 5 nM baﬁlomycin A1 [concentrations were established from
(Adamson et al., 2011)] and infected with inﬂuenza A H1N1. 24 h
later the media was replaced with low glucose media (with no
baﬁlomycin A1). Cells were immunostained with anti-HA antibody
24 h later.
Viability
Cells were removed from the culture plates with Cell Stripper
(Cellgro), washed with 1PBS, and incubated with Guava Via-
Count for 5 min. Viability was measured with the ViaCount
program of a Guava InCyte ﬂow cytometer.
SNARF-1 staining
MDCK cells were plated in low (1 mg/ml) or high (6 mg/ml)
glucose for 24 h. The pH-sensitive SNARF-1 dye (Molecular Probes)
was added to cells to a ﬁnal concentration of 1 μM for 30 min at
37 1C. Cells were rinsed twice with 1 PBS and mounted in 10%
H.P. Kohio, A.L. Adamson / Virology 444 (2013) 301–309 309glycerol in 1xPBS. Live cells were immediately imaged on an
Olympus confocal microscope with a single excitation wavelength
of 480 nm and the two emission wavelengths of 580 nm (higher
ﬂuorescence intensity denotes acidity) and 640 nm (higher ﬂuor-
escence intensity denotes basicity). Fluorescence intensities were
quantiﬁed with FluoView software and the ratios of the 580 nm/
640 nm intensities calculated.
Quantiﬁcation and statistics
To determine the percentage of infected cells for a given
condition, slides of cells were methodically scanned, and every
distinct ﬁeld that contained infected cells (where possible) were
imaged via confocal microscopy. Multiple ﬁelds of cells (at least
4 ﬁelds for each condition), typically containing at least 100 cells/
ﬁeld, were assessed as to the total number of cells (by counting
Hoescht-stained nuclei), and the infected cells (by counting cells
with HA staining). P values were determined using the student
T-test in Excel.Acknowledgments
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